Skip to content

Study · Measured the body's own peptide · 2025

3 results

Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease?

Girişgen İ, Altıncık SA, Avcı E, Öcal M, Becerir T, Malaş Öztekin G, Özhan B, Yüksel S

Journal of clinical research in pediatric endocrinology23 Dec 2024Cited by 1 (Europe PMC)

PMID39711006 (opens in a new tab)PMCIDPMC12118320 (opens in a new tab)DOI10.4274/jcrpe.galenos.2024.2024-5-6 (opens in a new tab)PepBankPUB-39711006
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In children, serum MOTS‑c levels were significantly lower in type 1 diabetes than in healthy controls.

    In plain wordsIn children, the body's own MOTS‑c levels were lower with type 1 diabetes than in healthy children.

    Peptide
    MOTS-c
    Outcome
    DecreaseSerum MOTS-c in T1DM versus healthy children
    Study

    n = 143

    Comparator
    Healthy controls
    Outcome group
    Mitochondrial function · Endocrine and hormones

    Source sentences

    Summary
    MOTS-c levels were significantly lower in the T1DM group than controls (76.2±1.3 vs 105.2±7.0, p<0.001).
    1 context sentence
    Summary · context
    The T1DM group included 82 [female:male (F:M) 1:1.64] patients while the controls numbered 61 (F:M 1:0.97), with respective mean ages of 14.3±3.3 and 10.6±4.2 years (p<0.01).

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In children with type 1 diabetes, serum MOTS‑c levels did not differ between subgroups by diabetes duration, obesity, metabolic control, hypertension, hyperlipidemia, glomerular hyperfiltration, eGFR decline or microalbuminuria.

    In plain wordsIn children with type 1 diabetes, the body's own MOTS‑c levels did not differ between the patient subgroups studied.

    Peptide
    MOTS-c
    Outcome
    No significant changeSerum MOTS-c across T1DM patient subgroups
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Endocrine and hormones

    Source sentences

    Summary
    No difference was found in MOTS-c levels between patient subgroups categorized by diabetes duration, obesity, metabolic control, hypertension, hyperlipidemia, glomerular hyperfiltration, decline in eGFR, and presence of microalbuminuria.
    1 context sentence
    Summary · context
    The T1DM group included 82 [female:male (F:M) 1:1.64] patients while the controls numbered 61 (F:M 1:0.97), with respective mean ages of 14.3±3.3 and 10.6±4.2 years (p<0.01).

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In children with type 1 diabetes, serum MOTS‑c was not predictive for diabetic kidney disease in simple linear regression.

    In plain wordsIn children with type 1 diabetes, the body's own MOTS‑c level did not predict early kidney disease.

    Peptide
    MOTS-c
    Outcome
    No significant changeMOTS-c as predictor of diabetic kidney disease
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Simple linear regression indicated that MOTS-c was not predictive for DKD.
    1 context sentence
    Summary · context
    The T1DM group included 82 [female:male (F:M) 1:1.64] patients while the controls numbered 61 (F:M 1:0.97), with respective mean ages of 14.3±3.3 and 10.6±4.2 years (p<0.01).

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.